OCEANSIDE, Calif., June 11, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire --Therapeutics Solutions International, Inc.,
(OTC Markets:TSOI) announced today initiation of efforts to combine its existing CTCFL "universal cancer antigen", labeled as
BRS-001, with its clinical stage StemVacs Dendritic Cell Platform.
The Company previously filed a patent on technologies covering novel means of stimulating the immune system to kill cancer using
naturally made nanoparticles termed "exosomes"1. The patent whose Mexican rights are licensed to the Pan Am Cancer
Treatment Centers covers the production and composition of matter of agents aimed at immunologically eradicating cancer stem cells.
In contrast to previous exosome-based cancer therapeutic approaches, the strategy disclosed in the patent involves focusing the
immune system to attack the CTCFL protein, which is selectively found on cancer stem cells2.
"The CTCFL or BORIS protein represents a unique onco-target in the fight against cancer since it is only found on cancer cells
and not healthy tissues. Our strategy possesses the possibility of inducing an immune response that would strike cancer at its very
roots, the cancer stem cells," said Timothy Dixon, President and CEO of Therapeutic Solutions International.
"The recently approved Right to Try Law allows for accelerated clinical development of therapeutics that possess Phase I data.
We plan to leverage this and other programs to take our scientific discoveries from the bench to the patient's bedside," said Dr.
James Veltmeyer, Member of the Company's Scientific Advisory Board.
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.
Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system.
The Company's corporate website is www.therapeuticsolutionsint.com and e-commerce at www.youcanordernow.com.
About Pan Am Cancer Treatment Center
Pan Am Cancer Treatment Center contact information:
Telephone: (619) 735-9581
Diego Rivera #2339 suite 108
Zona Rio, Tijuana B.C. 22010
www.cancerimmunotherapy.mx
info@cancerimmunotherapy.mx
1 https://patents.google.com/patent/US20170143812
2Asano et al. Oncotarget. 2016 Feb 3. https://www.ncbi.nlm.nih.gov/pubmed/?term=26849232
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could,"
"expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these
words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these
statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press
release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy,
outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future
events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and
uncertainties that could cause actual results to differ materially from the statements made.
CONTACT INFORMATION
Therapeutic Solutions International, Inc.
ir@tsoimail.com
